Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy

Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancers. The expected 5-year survival of stage III NSCLC ranges from 13% to 36% for stage III. Due to the heterogeneity and poor efficacy of stage III patients, there is great controversy on how to optimize the therapy strategy. I...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Transl Lung Cancer Res
Autors principals: Yang, Zhang-Ru, Liu, Mi-Na, Yu, Jia-Hua, Yang, Yun-Hai, Chen, Tian-Xiang, Han, Yu-Chen, Zhu, Lei, Zhao, Ji-Kai, Fu, Xiao-Long, Cai, Xu-Wei
Format: Artigo
Idioma:Inglês
Publicat: AME Publishing Company 2020
Matèries:
Review Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7653116/
https://ncbi.nlm.nih.gov/pubmed/33209626
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr-20-896
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars